2022 Tang Prize Masters’ Forum Series Sheds Light on Current Global Challenges
TAIPEI, Oct. 14, 2022 /PRNewswire/ -- Established by Dr. Samuel Yin in 2012, the Tang Prize celebrates its 10th anniversary this year with the 2022 Tang Prize Masters' Forum series that came to a successful conclusion in September. Six 2022 laureates, Professor Jeffrey Sachs for Sustainable Development, Drs. Katalin Kariko, Drew Weissman, Pieter Cullis for Biopharmaceutical Science, Professor Dame...
StarHub Launches Digital Health Service with Alexandra Hospital and ConnectedLife with Fitbit to Connect Patients with Doctors, Health Coaches and Caregivers
Personalised health and lifestyle app which integrates consenting users' Fitbit data First health tracking app that links a patient to a family doctor or General Practitioner (GP), health coach and caregiver to better manage pre- and non-complex chronic conditions Alexandra Hospital is the first hospital to onboard the new service and it is helping to connect the...
WuXi Biologics Receives “Best CDMO Award of the Year”
SHANGHAI, Oct. 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received the "Best CDMO Award of the Year" at the Asia-Pacific Biologics CMO Excellence Awards (APBCEA) 2022 hosted by IMAPAC. Over the years since 2017, WuXi Biologics has received multiple awards in various categories...
Fosun Pharma’s MSCI ESG Rating Upgraded to A
SHANGHAI, Oct. 14, 2022 /PRNewswire/ -- The world's leading index company Morgan Stanley Capital International ("MSCI") recently announced its latest annual Environmental, Social and Governance ("ESG") rating results. In recognition of its outstanding performance in ESG, MSCI upgraded the ESG rating of Fosun Pharma (stock code: 600196.SH, 02196.HK) from BBB to A, ranking the top level in China. Fosun...
Health Canada Approves Illuccix® for Prostate Cancer Imaging
MELBOURNE, Australia, Oct. 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that Health Canada has approved Illuccix® for use in staging and re-staging intermediate and high-risk prostate cancer and localizing tumour tissue in recurrent prostate cancer. Illuccix™ , after radiolabeling with gallium (68Ga), is indicated for use with...
Transcenta to Present Two Scientific Posters at SITC 2022 Annual Meeting
SUZHOU, China, Oct. 14, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it will present two scientific posters at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, November 8-12, 2022: one related to Claudin18.2...
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received approval in Australia from...
3M V.A.C. Therapy negative pressure wound therapy achieves key medical evidence milestone, surpassing 2,000 peer-reviewed medical journal studies published
ST. PAUL, Minn., Oct. 13, 2022 /PRNewswire/ -- 3M Health Care's Medical Solutions Division today announced its 3M™ V.A.C.® Therapy negative pressure wound therapy (NPWT) has surpassed a clinical evidence milestone of 2,000 published, peer-reviewed medical journal studies. V.A.C. Therapy is the first and only NPWT solution to garner this number of published...
First in North America: Jolly Good Hosts Clinical VR Multi Seminar in Boston, Aiming for Mass Production of UGC Medical VR
At the Boston Convention Center on Tuesday, October 25, 2022 TOKYO, Oct. 13, 2022 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as "Jolly Good") will hold a large-scale seminar on clinical training VR produced by the UGC* medical VR platform "JOLLYGOOD+" (Jolly Good Plus) on Tuesday, October 25, 2022, in Boston in the U.S....
Research Collaboration between Prof. Antonio Gasbarrini team at Gemelli Hospital and Asian Biotech companies, Coree and Dx&Vx
SEOUL, South Korea, Oct. 13, 2022 /PRNewswire/ -- According to International Diabetes Federation, approximately 537 million adults (20-79 years) are living with diabetes worldwide and 206 million adults of the Western Pacific region including China, Japan, and South Korea have diabetes in 2021. Studies have shown that Asians are at higher risk of developing type 2 diabetes compared with...
